People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| bluebird bio, Inc. | — | Biotechnology | Series C | $187.5M | $1.9B | 2012 |
| SpringWorks Therapeutics, Inc. | — | Pharma | Series D+ | $125.0M | $4.4B | 2019 |
| Translate Bio, Inc. | — | Biotechnology | Series C | $98.5M | $1.9B | 2019 |
| Blueprint Medicines Corp | — | Biotechnology | Series C | $73.2M | $2.0B | 2014 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2013 |
| Eleven Biotherapeutics, Inc. | — | Biotechnology | Series B | $43.3M | $39.5M | 2014 |
Daniel S. Lynch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel S. Lynch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Jean-Francois Formela | 1 | 17 |
| Peter Barton Hutt | 1 | 14 |
| Robert S Langer | 1 | 14 |
| Brian Gallagher | 1 | 11 |
| James Wright | 1 | 9 |
| Noubar Afeyan | 1 | 9 |
| Mark Levin | 1 | 9 |
| Scott Minick | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Robert Tepper | 1 | 7 |
| CARL L. GORDON | 1 | 7 |
| Alexis Borisy | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Chip Baird | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Omid Farokhzad | 1 | 4 |
| Edward Schnipper | 1 | 4 |
| Owen Hughes | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.